Similarly, a large population-based analysis suggested that inflammatory disorders characterized by systemic TNF-α activity, including psoriasis, may elevate AD risk, whereas anti-TNF-α therapy appears to mitigate this effect [62]. The gene discussed is TNF; the disease is psoriasis.